| Detailed information |
|---|
| CancerLivER ID | 2562 |
| Biomarker | galectin-3,serine/threonine kinase, translation factor eIF- 4A, -4B, -3, fibroblast growth factor receptor, and ri- bosomal protein L35A |
| Biomarker Name/Symbol (given in Publication) | galectin-3,serine/threonine kinase SGK, translation factor eIF- 4A, -4B, -3, fibroblast growth factor receptor, and ri- bosomal protein L35A |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential Diagnostic marker for HCC; but not validated on independent dataset |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC |
| Level of significance | |
| Source | Tissue |
| PMID | 12521301 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | 8 pairs of primary HCCs and the corresponding non-tumorous portion of the liver-needle-biopsy samples; Eight cases of HCC were named from Hepa-1 to Hepa-8. A pathological examination showed that Hepa-1, -2, -5, -8 were poorly-differentiated solid HCC types, and Hepa-3, -4, -6, -7 were well-different |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC v/s non-tumor |
| Year of Publication | 2002 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |